Cannabinoids in the management of spasticity associated with multiple sclerosis.
about
Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic reviewA new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis.Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedsideEffects on immune cells of a new 1,8-naphthyridin-2-one derivative and its analogues as selective CB2 agonists: implications in multiple sclerosis.Chronic administration during early adulthood does not alter the hormonally-dependent disruptive effects of delta-9-tetrahydrocannabinol (Δ9-THC) on complex behavior in female rats
P2860
Cannabinoids in the management of spasticity associated with multiple sclerosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cannabinoids in the management of spasticity associated with multiple sclerosis.
@en
Cannabinoids in the management of spasticity associated with multiple sclerosis.
@nl
type
label
Cannabinoids in the management of spasticity associated with multiple sclerosis.
@en
Cannabinoids in the management of spasticity associated with multiple sclerosis.
@nl
prefLabel
Cannabinoids in the management of spasticity associated with multiple sclerosis.
@en
Cannabinoids in the management of spasticity associated with multiple sclerosis.
@nl
P2860
P356
P1476
Cannabinoids in the management of spasticity associated with multiple sclerosis
@en
P2093
Maria Chiara Proto
Maurizio Bifulco
P2860
P304
P356
10.2147/NDT.S3208
P407
P577
2008-10-01T00:00:00Z